hotspot -WSS

hotspot

author：hotspot 2025-09-05 11:24:11 - browse：42734

3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT — Adobe

Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Medical mystery: When a cough is not just a cough

WSS

How digital tools helped lower hypertension in marginalized patients

UCLA team creates talking throat patch for voice disorders

Why depression after traumatic brain injury is distinct

How to save health care price transparency rules

Key House Republican on health care plans exit from Congress

EPA limits use of carcinogenic gas for sterilizing medical devices

focus

hotspot

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

HHS secretary Becerra pressed on Change HealthCare cyberattack

Supreme Court strikes down use of affirmative action

President Biden's budget: Here's what you might have missed

Continuity nursing helped my family in our darkest PICU moments

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Supreme Court strikes down use of affirmative action

The dental labor crisis is a moment of opportunity

Malaria cases in Florida and Texas: Here’s what you need to know

'Revelatory' study finds a smoking impact that remains after quitting

entertainment

Readout LOUD podcast: How biotech is using artificial intelligence

First U.S. drug developed to treat liver disease MASH is approved

John Green on his newest strategy for fighting tuberculosis

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

As AI in medicine takes off, can 'human in the loop' prevent harm?

For Medicare Advantage, Democrats want stronger protections around AI

focus

leisure time

focus

entertainment